TITLE

The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients

AUTHOR(S)
Van der Auwera, I.; Elst, H. J.; Van Laere, S. J.; Maes, H.; Huget, P.; Van Dam, P.; Van Marck, E. A.; Vermeulen, P. B.; Dirix, L. Y.
PUB. DATE
April 2009
SOURCE
British Journal of Cancer;4/21/2009, Vol. 100 Issue 8, p1277
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Circulating tumour cells (CTC) and tumour-related methylated DNA in blood have been separately assessed for their utility as a marker for subclinical metastasis in breast cancer. However, no studies have looked into the relation between the both molecular markers in this type of cancer. In this study, we investigated the correlations between total/methylated DNA and CTC in the blood from metastatic breast cancer patients. We simultaneously obtained whole blood, plasma and serum samples from 80 patients and 20 controls. The CellSearch System was used to enumerate CTC in blood samples. Plasma total DNA levels were determined by a QPCR method. Sera were analysed by methylation-specific QPCR for three markers: adenomatous polyposis coli (APC), ras association domain family protein 1A (RASSF1A) and oestrogen receptor 1 (ESR1). Total DNA levels in patients were significantly increased when compared with controls (P<0.001) and correlated with the number of CTC (r=0.418, P<0.001). Hypermethylation of one or more genes was detected in 42 (53%) serum samples from breast cancer patients and in three (16%) serum samples from controls (P=0.003). APC was hypermethylated in 29%, RASSF1A in 35% and ESR1 in 20% of breast cancer cases. Detection of a methylated gene in serum was associated with the detection of CTC in blood (P=0.03). The detection of large amounts of circulating total/methylated DNA correlated with the presence of CTC in the blood from patients with breast cancer. This can be interpreted in two ways: (a) CTC are a potential source of circulating tumour-specific DNA; (b) high numbers of CTC and circulating methylated DNA are both a phenotypic feature of more aggressive tumour biology.British Journal of Cancer (2009) 100, 1277–1286. doi:10.1038/sj.bjc.6605013 www.bjcancer.com
ACCESSION #
37591408

 

Related Articles

  • Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Baccelli, Irène; Schneeweiss, Andreas; Riethdorf, Sabine; Stenzinger, Albrecht; Schillert, Anja; Vogel, Vanessa; Klein, Corinna; Saini, Massimo; Bäuerle, Tobias; Wallwiener, Markus; Holland-Letz, Tim; Höfner, Thomas; Sprick, Martin; Scharpff, Martina; Marmé, Frederik; Sinn, Hans Peter; Pantel, Klaus; Weichert, Wilko; Trumpp, Andreas // Nature Biotechnology;Jun2013, Vol. 31 Issue 6, p539 

    It has been hypothesized that carcinoma metastasis is initiated by a subpopulation of circulating tumor cells (CTCs) found in the blood of patients. However, although the presence of CTCs is an indicator of poor prognosis in several carcinoma entities, the existence and phenotype of...

  • Assessment of γ-H2AX levels in circulating tumor cells from patients receiving chemotherapy. Garcia-Villa, Alejandra; Balasubramanian, Priya; Miller, Brandon L.; Lustberg, Maryam B.; Ramaswamy, Bhuvaneswari; Chalmers, Jeffrey J. // Frontiers in Oncology;Sep2012, Vol. 2, p1 

    Circulating tumor cells (CTCs) are prognostic markers in a variety of solid tumor malignancies. The potential of CTCs to be used as a "liquid biopsy" to monitor a patient's condition and predict drug response and resistance is currently under investigation. Using a negative depletion, enrichment...

  • Specific 5'CpG Island Methylation Signatures of FHIT and p16 Genes and Their Potential Diagnostic Relevance in Indian Breast Cancer Patients. Naqvi, Raza Ali; Hussain, Arif; Raish, Mohmammad; Noor, Afshan; Shahid, Mohammad; Sarin, Ritu; Kukreti, Himani; Khan, Nida Jameel; Ahmad, Shandar; Deo, Suryanarayan V. S.; Husain, Syed Akhtar; Pasha, Syed Tazeen; Basir, Seemi Farhat; Shukla, Nootan Kumar // DNA & Cell Biology;Sep2008, Vol. 27 Issue 9, p517 

    Even after tremendous molecular studies, early detection, more accurate and sensitive diagnosis, and prognosis of breast cancer appear to be a riddle so far. To stab the enigma, this study is designed to envisage DNA methylation signatures as cancer-specific and stage-specific biomarkers in...

  • Levels of specific serum N-glycans identify breast cancer patients with higher circulating tumor cell counts. Saldova, R.; Reuben, J. M.; Abd Hamid, U. M.; Rudd, P. M.; Cristofanilli, M. // Annals of Oncology;May2011, Vol. 22 Issue 5, p1113 

    Background: Metastatic breast cancer (MBC) is currently an incurable condition that is primarily treated with palliative measures. Isolation of circulating tumor cells (CTCs) from the peripheral blood of these patients provides a predictive prognostic indicator, independent of the type of...

  • The shifting landscape of metastatic breast cancer to the CNS. Quigley, Matthew; Fukui, Olivia; Chew, Brandon; Bhatia, Sanjay; Karlovits, Steven // Neurosurgical Review;Jul2013, Vol. 36 Issue 3, p377 

    The improved survival following the diagnosis of breast cancer has potentially altered the characteristics and course of patients presenting with CNS involvement. We therefore sought to define our current cohort of breast cancer patients with metastatic disease to the CNS in regard to modern...

  • A potential prognostic long non-coding RNA signature to predict metastasis-free survival of breast cancer patients. Sun, Jie; Chen, Xihai; Wang, Zhenzhen; Guo, Maoni; Shi, Hongbo; Wang, Xiaojun; Cheng, Liang; Zhou, Meng // Scientific Reports;11/13/2015, p16553 

    Long non-coding RNAs (lncRNAs) have been implicated in a variety of biological processes, and dysregulated lncRNAs have demonstrated potential roles as biomarkers and therapeutic targets for cancer prognosis and treatment. In this study, by repurposing microarray probes, we analyzed lncRNA...

  • The elevated preoperative platelet-to-lymphocyte ratio predicts poor prognosis in breast cancer patients. Krenn-Pilko, S; Langsenlehner, U; Thurner, E-M; Stojakovic, T; Pichler, M; Gerger, A; Kapp, K S; Langsenlehner, T // British Journal of Cancer;5/13/2014, Vol. 110 Issue 10, p2524 

    Background:The elevation of the platelet-to-lymphocyte ratio (PLR), an easily applicable blood test based on platelet and lymphocyte counts has been associated with poor prognosis in patients with different types of cancer. The present study was aimed to investigate the prognostic significance...

  • Methylation status and protein expression of RASSF1A in breast cancer patients. Hagrass, Hoda; Pasha, Heba; Shaheen, Mohamed; Abdel Bary, Eman; Kassem, Rasha // Molecular Biology Reports;Jan2014, Vol. 41 Issue 1, p57 

    Recently genetics and epigenetics alterations have been found to be characteristic of malignancy and hence can be used as targets for detection of neoplasia. RAS association domain family protein 1A (RASSF1A) gene hypermethylation has been a subject of interest in recent researches on cancer...

  • Methylation signature of lymph node metastases in breast cancer patients. Barekati, Zeinab; Radpour, Ramin; Quing Lu; Bitzer, Johannes; Hong Zheng; Toniolo, Paolo; Lener, Per; Xiao Yan Zhong // BMC Cancer;2012, Vol. 12 Issue 1, p244 

    Background: Invasion and metastasis are two important hallmarks of malignant tumors caused by complex genetic and epigenetic alterations. The present study investigated the contribution of aberrant methylation profiles of cancer related genes, APC, BIN1, BMP6, BRCA1, CST6, ESR-b, GSTP1, P14...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics